Kite teams up with Sangamo to treat cancer
26-02-2018
Life sciences companies face off over ‘Juno’ trademark
26-07-2017
Novartis pays Juno $12m in cancer patent licensing deal
07-04-2015
wildpixel / iStockphoto.com
Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Kite, Sloan Kettering Institute, Juno, cancer immunotherapy, US Patent and Trade Office, Patent Trial and Appeal Board, Food and Drug Administration, paten
